Trevi's Phase Three Timeline and Cash Burn Rate Take Center Stage Tomorrow

Trevi Therapeutics (NASDAQ: TRVI) reports first-quarter 2026 earnings tomorrow, May 5, after market close, with analysts expecting continued losses as the clinical-stage biotech advances its investigational therapy Haduvio through pivotal trials. The central question: can TRVI maintain its streak of four consecutive earnings beats while demonstrating progress toward regulatory approval for chronic cough treatments in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC)? With the stock trading well above all major moving averages and analyst price targets implying significant upside, investor focus will center on Phase 3 trial timelines and the path to commercialization.

Part 1: Earnings Preview

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER) for chronic cough in patients with IPF, non-IPF interstitial lung disease, and refractory chronic cough—conditions with no FDA-approved therapies and substantial unmet need across an estimated 2-3 million U.S. patients. The company's investigational therapy has shown statistically significant cough frequency reductions in clinical trials, positioning it as a potential first-in-class treatment.

TRVI will report Q1 2026 results tomorrow, May 5, after market close. Analysts expect an EPS loss of $-0.07 on no revenue, representing a 22% improvement from the $-0.09 loss reported in Q1 2025. The most recent quarter (Q4 2025) delivered an EPS of $-0.06, beating estimates of $-0.10 by 40%—the fourth consecutive quarterly beat.

Three key themes define this earnings story:

1. Phase 3 Trial Momentum and FDA Pathway Clarity: Following positive Phase 2b CORAL trial data showing a 60.2% reduction in 24-hour cough frequency at the highest dose, investors are watching for updates on Phase 3 trial initiation timelines and regulatory strategy. The company announced FDA alignment on the Phase 3 program design, making execution updates critical. Analysts view the regulatory pathway as increasingly de-risked, with multiple firms citing the therapy's differentiated mechanism of action as a kappa agonist and mu antagonist (KAMA).

2. Cash Runway and Financing Strategy: With $200 million in cash as of March 2026 and a market cap of $1.6 billion, TRVI's ability to fund operations through pivotal trials without dilutive financing remains a focal point. General and administrative expenses rose $3.8 million year-over-year in 2025 to $15.9 million, driven by higher professional fees and personnel costs. Investors will scrutinize burn rate guidance and whether the current cash position supports the company through key Phase 3 milestones.

3. Competitive Positioning Against GSK and Market Expansion Potential: With GSK's competing chronic cough therapy in development, TRVI's ability to differentiate Haduvio's safety profile—particularly given nalbuphine's non-scheduled status by the DEA—becomes increasingly important. The company's expansion into non-IPF ILD (an additional 228,000 U.S. patients) and upcoming presentations at the American Thoracic Society conference could validate the therapy's broader applicability and commercial opportunity.

Leading analysts remain overwhelmingly bullish heading into the release. The consensus maintains a Strong Buy rating with 11 of 13 analysts at Strong Buy, and the $21.83 mean price target implies 52% upside. Recent analyst commentary emphasizes the therapy's "best-in-class potential" and "significant commercial opportunity in underserved markets," with several firms highlighting the 165-patient CORAL trial enrollment as evidence of strong clinical execution. One analyst noted that "the consistent beat pattern and improving loss trajectory suggest operational discipline as the company scales toward commercialization."

Part 2: Historical Earnings Performance

TRVI has established a consistent pattern of beating earnings estimates over the past four quarters, with surprises ranging from +10% to +40%. The company reported losses of $-0.09, $-0.09, $-0.08, and $-0.06 in Q1 2025, Q2 2025, Q3 2025, and Q4 2025 respectively, beating consensus estimates in every instance.

The trend shows meaningful improvement in loss reduction. Losses have narrowed from $-0.09 in Q1 2025 to $-0.06 in Q4 2025, representing a 33% improvement over three quarters. The magnitude of beats has also accelerated, with Q4 2025's 40% surprise marking the strongest outperformance in the trailing four quarters. This pattern suggests either conservative analyst modeling or effective expense management as the company advances through clinical development.

Comparing year-over-year performance, the Q1 2026 consensus estimate of $-0.07 represents a 22% improvement versus the $-0.09 reported in Q1 2025, indicating analysts expect the loss-narrowing trajectory to continue. However, the estimate for Q1 2026 actually represents a slight widening from Q4 2025's $-0.06 result, likely reflecting increased spending on Phase 3 trial preparation and regulatory activities.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

TRVI reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual earnings data.

Historical price behavior shows moderate volatility around earnings releases, with the stock exhibiting an average absolute Day 0 move of 2.16% and Day +1 move of 3.53%. Intraday ranges are more pronounced, averaging 6.11% on Day 0 and 10.37% on Day +1, indicating significant intraday volatility even when closing moves are more contained.

The most recent earnings release on March 17, 2026 saw minimal Day 0 movement (+0.27%) but a notable Day +1 decline of -4.47% despite the 40% earnings beat, suggesting investors may have sold on the news or reacted to forward guidance. Prior quarters showed mixed directional patterns—the November 2025 release triggered declines on both days (-3.29% Day 0, -0.79% Day +1), while August 2025 saw modest gains on both days.

The lack of consistent directional bias in post-earnings moves suggests TRVI's price action is highly dependent on qualitative factors beyond the EPS beat/miss—likely trial updates, timeline guidance, and cash burn commentary rather than the quarterly loss figure itself. Investors should prepare for potential swings in either direction regardless of whether the company beats estimates again.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 9.81% (±$1.41) for the May 15 expiration, which is significantly higher than the average historical Day +1 move of 3.53% but roughly in line with the average Day +1 intraday range of 10.37%. This elevated implied volatility of 66.18% suggests options traders are anticipating larger-than-typical price swings, possibly reflecting heightened uncertainty around Phase 3 trial updates or financing announcements that could accompany the earnings release.

Part 3: What Analysts Are Saying

Analysts maintain strong conviction on TRVI heading into earnings, with the consensus at 4.77 out of 5.0—firmly in Strong Buy territory. The rating breakdown shows 11 Strong Buys, 1 Moderate Buy, and 1 Hold, with zero sell ratings. The average price target of $21.83 implies 52% upside from the current price of $14.38, with a high target of $27.00 (88% upside) and a low target of $16.00 (11% upside).

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.77. This stability suggests analysts are maintaining their bullish stance rather than adjusting views ahead of the earnings release, likely reflecting confidence in the company's clinical progress and regulatory pathway following the positive CORAL trial data.

The wide range between high and low price targets ($11 spread) reflects differing assumptions about commercial potential and probability of regulatory success, but even the most conservative target implies double-digit upside. The consensus view appears anchored on Haduvio's differentiated mechanism, the large addressable market across IPF and RCC indications, and the lack of approved competing therapies—factors that support premium valuations for clinical-stage biotechs with de-risked regulatory pathways.

Part 4: Technical Picture

TRVI enters earnings with strong technical momentum across all timeframes. The Barchart Technical Opinion currently stands at 100% Buy, up from 100% Buy last week and 56% Buy last month, indicating a significant strengthening of the technical picture over the past 30 days.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the earnings release
• Medium-term (100% Buy): Bullish reading confirms strength in the intermediate timeframe, suggesting the recent rally has staying power
• Long-term (100% Buy): Strong buy signal reflects positive longer-term trend structure, indicating the stock has established a sustained uptrend

Trend Characteristics: The Strong strength combined with Strongest direction signals an exceptionally robust technical environment, suggesting powerful momentum and minimal resistance heading into earnings.

The stock is trading at $14.38, positioned above all major moving averages: the 5-day ($13.93), 10-day ($14.20), 20-day ($14.07), 50-day ($12.60), 100-day ($12.05), and 200-day ($10.72). This alignment with the stock above every key moving average is a classic bullish configuration, indicating strong trend support across multiple timeframes.

The 50-day moving average at $12.60 represents the nearest significant support level, approximately 12% below current prices, while the stock's position above shorter-term averages suggests limited near-term resistance. The 34% gain above the 200-day moving average reflects the strength of the rally since late 2025, though this extended positioning also introduces potential downside risk if earnings disappoint. The overall technical setup is highly supportive heading into earnings, with momentum indicators, moving average alignment, and the Barchart Opinion all signaling bullish conditions—though the magnitude of the recent advance suggests volatility could be elevated in either direction depending on trial updates and guidance.